JP2014526533A - Ｐｄｅ１０ａ阻害剤としてのトリアゾロピリジン化合物 - Google Patents

Ｐｄｅ１０ａ阻害剤としてのトリアゾロピリジン化合物 Download PDF

Info

Publication number
JP2014526533A
JP2014526533A JP2014531187A JP2014531187A JP2014526533A JP 2014526533 A JP2014526533 A JP 2014526533A JP 2014531187 A JP2014531187 A JP 2014531187A JP 2014531187 A JP2014531187 A JP 2014531187A JP 2014526533 A JP2014526533 A JP 2014526533A
Authority
JP
Japan
Prior art keywords
methyl
triazolo
pyridin
pyrazole
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014531187A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014526533A5 (enExample
Inventor
フロール，アレキサンダー
グレープケ・ツビンデン，カトリン
コーナー，マティアス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46851999&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2014526533(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2014526533A publication Critical patent/JP2014526533A/ja
Publication of JP2014526533A5 publication Critical patent/JP2014526533A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2014531187A 2011-09-19 2012-09-17 Ｐｄｅ１０ａ阻害剤としてのトリアゾロピリジン化合物 Pending JP2014526533A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11181752.4 2011-09-19
EP11181752 2011-09-19
PCT/EP2012/068203 WO2013041472A1 (en) 2011-09-19 2012-09-17 Triazolopyridine compounds as pde10a inhibitors

Publications (2)

Publication Number Publication Date
JP2014526533A true JP2014526533A (ja) 2014-10-06
JP2014526533A5 JP2014526533A5 (enExample) 2015-07-30

Family

ID=46851999

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014531187A Pending JP2014526533A (ja) 2011-09-19 2012-09-17 Ｐｄｅ１０ａ阻害剤としてのトリアゾロピリジン化合物

Country Status (19)

Country Link
US (2) US8946427B2 (enExample)
EP (1) EP2758396B1 (enExample)
JP (1) JP2014526533A (enExample)
KR (1) KR101584925B1 (enExample)
CN (1) CN103827114B (enExample)
AU (1) AU2012311713A1 (enExample)
BR (1) BR112014006248A2 (enExample)
CA (1) CA2846758C (enExample)
CL (1) CL2014000641A1 (enExample)
CO (1) CO6900144A2 (enExample)
EA (1) EA201490599A1 (enExample)
ES (1) ES2626801T3 (enExample)
IL (1) IL231403A0 (enExample)
MX (1) MX2014003025A (enExample)
PE (1) PE20141553A1 (enExample)
PH (1) PH12014500499A1 (enExample)
SG (1) SG11201400759RA (enExample)
UA (1) UA108711C2 (enExample)
WO (1) WO2013041472A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020531489A (ja) * 2017-08-22 2020-11-05 バイエル・アクチエンゲゼルシヤフト 有害生物防除剤としてのヘテロサイクレン誘導体

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2757883B1 (en) * 2011-09-22 2021-01-13 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
WO2013043518A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
MX2015014729A (es) * 2013-04-30 2016-03-07 Hoffmann La Roche Acoplamiento de pirazol-amidas catalizadas con paladio.
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
WO2016017719A1 (ja) * 2014-07-30 2016-02-04 持田製薬株式会社 ピラゾール誘導体の製造方法
CA2956262A1 (en) 2014-07-30 2016-02-04 Mochida Pharmaceutical Co., Ltd. Pyrazole derivative manufacturing method
CN112608300B (zh) 2015-03-11 2024-04-26 Fmc公司 杂环取代的二环唑杀有害生物剂
ES2778628T3 (es) 2015-03-12 2020-08-11 Fmc Corp Pesticidas de azol bicíclico sustituido con heterociclo
BR112018007034B1 (pt) 2015-10-08 2022-10-11 Fmc Corporation Composto, composição, método para controlar uma praga de invertebrados e semente revestida
US12116370B2 (en) 2019-05-27 2024-10-15 Nihon Nohyaku Co., Ltd. Condensed heterocyclic compound having a bridgehead nitrogen atom or salt thereof, agricultural or horticultural insecticide comprising the compound, and method for using the insecticide
AR119140A1 (es) 2019-06-13 2021-11-24 Pi Industries Ltd Compuestos heterocíclicos fusionados y su uso como agentes de control de plagas
CN110396157B (zh) * 2019-08-07 2021-07-30 广州市建筑科学研究院有限公司 缓释型聚羧酸纳米减水剂及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010035745A1 (ja) * 2008-09-25 2010-04-01 杏林製薬株式会社 ヘテロ環ビアリール誘導体及びそれらを有効成分とするｐｄｅ阻害剤
WO2011036127A1 (en) * 2009-09-24 2011-03-31 F. Hoffmann-La Roche Ag Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors
WO2011072697A1 (en) * 2009-12-17 2011-06-23 H. Lundbeck A/S Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors
WO2011072695A1 (en) * 2009-12-17 2011-06-23 H. Lundbeck A/S Phenylimidazole derivatives comprising an ethynylene linker as pde10a enzyme inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355653B1 (en) * 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
WO2005012485A2 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
NL2000397C2 (nl) * 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
WO2010059836A1 (en) * 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
US8685967B2 (en) * 2009-04-07 2014-04-01 Merck Sharp & Dohme Corp. Substituted triazolopyridines and analogs thereof
CN112019976B (zh) 2009-11-24 2024-09-27 诺基亚技术有限公司 用于处理音频信号的设备和方法
TWI485151B (zh) * 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010035745A1 (ja) * 2008-09-25 2010-04-01 杏林製薬株式会社 ヘテロ環ビアリール誘導体及びそれらを有効成分とするｐｄｅ阻害剤
WO2011036127A1 (en) * 2009-09-24 2011-03-31 F. Hoffmann-La Roche Ag Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors
WO2011072697A1 (en) * 2009-12-17 2011-06-23 H. Lundbeck A/S Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors
WO2011072695A1 (en) * 2009-12-17 2011-06-23 H. Lundbeck A/S Phenylimidazole derivatives comprising an ethynylene linker as pde10a enzyme inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6015008744; Ｐａｔｒｉｃｋ　Ｒ．　Ｖｅｒｈｏｅｓｔ，　ｅｔ　ａｌ．: Ｊ．　Ｍｅｄ．　Ｃｈｅｍ． Ｖｏｌ．５２, 2009, ｐｐ．５１８８-５１９６ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020531489A (ja) * 2017-08-22 2020-11-05 バイエル・アクチエンゲゼルシヤフト 有害生物防除剤としてのヘテロサイクレン誘導体
JP7202360B2 (ja) 2017-08-22 2023-01-11 バイエル・アクチエンゲゼルシヤフト 有害生物防除剤としてのヘテロサイクレン誘導体

Also Published As

Publication number Publication date
US8946427B2 (en) 2015-02-03
AU2012311713A1 (en) 2014-03-13
CN103827114A (zh) 2014-05-28
EP2758396A1 (en) 2014-07-30
MX2014003025A (es) 2014-05-28
CO6900144A2 (es) 2014-03-20
KR20140075716A (ko) 2014-06-19
CA2846758A1 (en) 2013-03-28
NZ621597A (en) 2015-04-24
UA108711C2 (uk) 2015-05-25
PE20141553A1 (es) 2014-10-30
US20150099735A1 (en) 2015-04-09
US9227970B2 (en) 2016-01-05
US20140303141A1 (en) 2014-10-09
ES2626801T3 (es) 2017-07-26
KR101584925B1 (ko) 2016-01-12
EP2758396B1 (en) 2017-03-29
WO2013041472A1 (en) 2013-03-28
CL2014000641A1 (es) 2014-11-14
CA2846758C (en) 2017-09-12
PH12014500499A1 (en) 2014-04-14
EA201490599A1 (ru) 2014-07-30
IL231403A0 (en) 2014-04-30
SG11201400759RA (en) 2014-07-30
BR112014006248A2 (pt) 2017-04-11
CN103827114B (zh) 2016-08-24

Similar Documents

Publication Publication Date Title
JP2014526533A (ja) Ｐｄｅ１０ａ阻害剤としてのトリアゾロピリジン化合物
JP5932828B2 (ja) トリアゾロピリジン化合物
US8470820B2 (en) Nitrogen-containing heteroaryl derivatives
US9150588B2 (en) Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors
EP2574607A1 (en) PDE10 modulators
JP2013534223A (ja) 縮合複素環化合物
US8883788B2 (en) Fused heterocyclic ring compound
US9090586B2 (en) Heterocyclic compound
NZ621597B2 (en) Triazolopyridine compounds as pde10a inhibitors
HK1193595A (en) Triazolopyridine compounds as pde10a inhibitors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150310

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150609

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20150609

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151208